{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:42:22Z","timestamp":1787794942321,"version":"build-2784847793"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010845","name":"Pancare Foundation","doi-asserted-by":"publisher","award":["APP1165978"],"award-info":[{"award-number":["APP1165978"]}],"id":[{"id":"10.13039\/100010845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023175","name":"Illawarra Cancer Carers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["2020\/CDF1093"],"award-info":[{"award-number":["2020\/CDF1093"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejps.2025.107359","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:55:06Z","timestamp":1762206906000},"page":"107359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Implantable drug delivery system improves tolerability of anti-CD40\/anti-PD1 and chemotherapy in a murine model of breast cancer"],"prefix":"10.1016","volume":"216","author":[{"given":"Samantha J.","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Minaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross J","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Penney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Beavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon G.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameera","family":"Ansar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Lochhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Aghmesheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-1149","authenticated-orcid":false,"given":"Kara L.","family":"Vine-Perrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107359_bib40","doi-asserted-by":"crossref","unstructured":"Adams, V.R., Adverse events associated with chemotherapy for common cancers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000. 20(7P2): p. 96S-103S.","DOI":"10.1592\/phco.20.10.96S.35230"},{"issue":"5","key":"10.1016\/j.ejps.2025.107359_bib0010","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: challenges and treatment options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2025.107359_bib0014","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2012","journal-title":"Adv. Drug Deliv. Rev"},{"key":"10.1016\/j.ejps.2025.107359_bib0003","doi-asserted-by":"crossref","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","article-title":"Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents","volume":"23","author":"Andr\u00e9","year":"2012","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.ejps.2025.107359_bib36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mabi.200600069","article-title":"Alginate hydrogels as biomaterials","volume":"6","author":"Augst","year":"2006","journal-title":"Macromolecular bioscience"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib58","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/s41467-020-15979-2","article-title":"Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy","volume":"11","author":"Baumann","year":"2020","journal-title":"Nature Communications"},{"issue":"6","key":"10.1016\/j.ejps.2025.107359_bib45","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer cell"},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib0011","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","article-title":"Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists","volume":"17","author":"Beatty","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2567.2010.03357.x","article-title":"Anti\u2010tumour synergy of cytotoxic chemotherapy and anti\u2010CD40 plus CpG\u2010ODN immunotherapy through repolarization of tumour\u2010associated macrophages","volume":"132","author":"Buhtoiarov","year":"2011","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.ejps.2025.107359_bib0009","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-21-0496","article-title":"IL15 and Anti\u2013PD-1 augment the efficacy of agonistic intratumoral anti-CD40 in a mouse model with multiple TRAMP-C2 tumors","volume":"28","author":"Chen","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ejps.2025.107359_bib30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.ejps.2025.107359_bib61","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s00262-021-02932-5","article-title":"The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo","volume":"70","author":"Deronic","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"7","key":"10.1016\/j.ejps.2025.107359_bib60","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/10495","article-title":"CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy","volume":"5","author":"Diehl","year":"1999","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Duan","year":"2021","journal-title":"Targeting macrophages in cancer immunotherapy. Signal transduction and targeted therapy"},{"key":"10.1016\/j.ejps.2025.107359_bib0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.mattod.2023.03.006","article-title":"Hydrogel-enabled, local administration and combinatorial delivery of immunotherapies for cancer treatment","volume":"65","author":"Erfani","year":"2023","journal-title":"Mater. Today"},{"issue":"3","key":"10.1016\/j.ejps.2025.107359_bib28","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib0002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejps.2025.107359_bib0023","article-title":"Recent progress in implantable drug delivery systems","author":"He","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ejps.2025.107359_bib0016","doi-asserted-by":"crossref","unstructured":"Hope, A., Wade, S.J., M. Aghmesheh, M., Vine, K.L. 2022. Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. 341: p. 399\u2013413.","DOI":"10.1016\/j.jconrel.2021.11.043"},{"issue":"5","key":"10.1016\/j.ejps.2025.107359_bib0006","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ijc.32141","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.ejps.2025.107359_bib35","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3109\/03639045.2014.917657","article-title":"Alginate drug delivery systems: application in context of pharmaceutical and biomedical research","volume":"40","author":"Jain","year":"2014","journal-title":"Drug development and industrial pharmacy"},{"key":"10.1016\/j.ejps.2025.107359_bib39","first-page":"1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","author":"Jayathilaka","year":"2024","journal-title":"British journal of cancer"},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.uct.2007.06.001","article-title":"Anti-CD40 agonist antibodies: preclinical and clinical experience","volume":"2","author":"Khalil","year":"2007","journal-title":"Update Cancer Ther."},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib44","first-page":"6","article-title":"PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer","volume":"14","author":"Kim","year":"2021","journal-title":"Models"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib38","first-page":"106","article-title":"Alginate: properties and biomedical applications","volume":"37","author":"Lee","year":"2012","journal-title":"polymer science"},{"key":"10.1016\/j.ejps.2025.107359_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.612950","article-title":"Implantable and injectable biomaterial scaffolds for cancer immunotherapy","volume":"8","author":"Li","year":"2020","journal-title":"Front. Bioeng Biotechnol."},{"issue":"7","key":"10.1016\/j.ejps.2025.107359_bib55","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"The Journal of experimental medicine"},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2020.07.2326","article-title":"Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1","volume":"110","author":"Liu","year":"2021","journal-title":"International Journal of Radiation Oncology* Biology* Physics"},{"issue":"9","key":"10.1016\/j.ejps.2025.107359_bib0008","article-title":"Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"issue":"6","key":"10.1016\/j.ejps.2025.107359_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10594","article-title":"Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ejps.2025.107359_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102258","article-title":"Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy","volume":"56","author":"Liu","year":"2024","journal-title":"Nano Today"},{"issue":"3","key":"10.1016\/j.ejps.2025.107359_bib50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","article-title":"A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell\u2013Mediated Anticancer ActivityVaccine, CD40 Agonist, and PD-1 Antagonist Antibody Therapy","volume":"7","author":"Ma","year":"2019","journal-title":"Cancer immunology research"},{"issue":"7","key":"10.1016\/j.ejps.2025.107359_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133385","article-title":"4T1 murine mammary carcinoma cells enhance macrophage-mediated innate inflammatory responses","volume":"10","author":"Madera","year":"2015","journal-title":"PLoS One"},{"issue":"7\u20139","key":"10.1016\/j.ejps.2025.107359_bib33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/09205063.2017.1394711","article-title":"PCL and PCL-based materials in biomedical applications","volume":"29","author":"Malikmammadov","year":"2018","journal-title":"Journal of Biomaterials science, Polymer edition"},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib41","article-title":"Repeated PD-1\/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast","volume":"5","author":"Mall","year":"2016","journal-title":"cancer"},{"issue":"10","key":"10.1016\/j.ejps.2025.107359_bib0017","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1007\/s12274-024-6980-z","article-title":"Innovative hydrogel-based delivery systems for immunotherapy: a review of pre-clinical progress","volume":"17","author":"Mamidi","year":"2024","journal-title":"Nano Res."},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1074-7613(02)00280-7","article-title":"CD4+ CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor","volume":"16","author":"McHugh","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.ejps.2025.107359_bib53","series-title":"Mucosal immunology","author":"Mestecky","year":"2015"},{"key":"10.1016\/j.ejps.2025.107359_bib0027","article-title":"Gut microbial diversity is preserved through localised chemo-immunotherapy delivery in a KPC mouse model of pancreatic cancer","volume":"19","author":"Minaei","year":"2025","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.ejps.2025.107359_bib42","first-page":"729","article-title":"Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror","volume":"13","author":"Monjazeb","year":"2021","journal-title":"Clinical Paradigms"},{"issue":"14","key":"10.1016\/j.ejps.2025.107359_bib51","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"12","key":"10.1016\/j.ejps.2025.107359_bib31","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Annals of Oncology"},{"issue":"15","key":"10.1016\/j.ejps.2025.107359_bib65","first-page":"4490","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer research"},{"key":"10.1016\/j.ejps.2025.107359_bib0013","series-title":"Abstract CT004: A Phase Ib study of CD40 Agonistic Monoclonal Antibody APX005M Together With Gemcitabine (Gem) and Nab-Paclitaxel (NP) With Or Without Nivolumab (Nivo) in Untreated Metastatic Ductal Pancreatic Adenocarcinoma (PDAC) Patients","author":"O'Hara","year":"2019"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib57","first-page":"8917804","article-title":"Macrophage polarization in chronic inflammatory diseases: killers or builders?","volume":"2018","author":"Parisi","year":"2018","journal-title":"Journal of immunology research"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jnt3010003","article-title":"Implantable devices for the treatment of breast cancer","volume":"3","author":"Pial","year":"2022","journal-title":"J. Nanotheranostics"},{"issue":"3","key":"10.1016\/j.ejps.2025.107359_bib34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ajps.2020.10.001","article-title":"Alginate and alginate composites for biomedical applications","volume":"16","author":"Raus","year":"2021","journal-title":"Asian Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejps.2025.107359_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940674","article-title":"Next generation CD40 agonistic antibodies for cancer immunotherapy","volume":"13","author":"Salomon","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib0007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","article-title":"Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer","volume":"2","author":"Sandin","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.ejps.2025.107359_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.ejps.2025.107359_bib48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nature Reviews Immunology"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib47","doi-asserted-by":"crossref","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","article-title":"PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2018","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.ejps.2025.107359_bib32","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.biomaterials.2005.09.019","article-title":"The in vivo degradation, absorption and excretion of PCL-based implant","volume":"27","author":"Sun","year":"2006","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.ejps.2025.107359_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1081\/DDC-120003853","article-title":"Alginate in drug delivery systems","volume":"28","author":"T\u00f8nnesen","year":"2002","journal-title":"Drug development and industrial pharmacy"},{"key":"10.1016\/j.ejps.2025.107359_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201706665","article-title":"Biopolymers for antitumor implantable drug delivery systems: recent advances and future outlook","author":"Talebian","year":"2018","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.ejps.2025.107359_bib0012","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107359_bib0026","doi-asserted-by":"crossref","unstructured":"Wade, S.J., A. Zuzic, J. Foroughi, S. Talebian, M. Aghmesheh, S.E. Moulton, and K.L. Vine, Preparation and in vitro assessment of wet-spun gemcitabine-loaded polymeric fibers: Towards localized drug delivery for the treatment of pancreatic cancer. 2017. 17(5): p. 795\u2013804.","DOI":"10.1016\/j.pan.2017.06.001"},{"key":"10.1016\/j.ejps.2025.107359_bib0025","doi-asserted-by":"crossref","unstructured":"Wade, S.J., Z. Sahin, A.K. Piper, S. Talebian, M. Aghmesheh, J. Foroughi, G.G. Wallace, S.E. Moulton, and K.L.J.A.H.M. Vine, Dual delivery of gemcitabine and paclitaxel by wet-spun coaxial fibers induces pancreatic ductal adenocarcinoma cell death, reduces tumor volume, and sensitizes cells to radiation. 2020: p. 2001115.","DOI":"10.1002\/adhm.202001115"},{"issue":"4","key":"10.1016\/j.ejps.2025.107359_bib63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","article-title":"Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic CarcinomaExtending Reach of Checkpoint Blockade in Pancreatic Cancer","volume":"3","author":"Winograd","year":"2015","journal-title":"Cancer immunology research"},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib62","doi-asserted-by":"crossref","first-page":"2044103","DOI":"10.1080\/2162402X.2022.2044103","article-title":"IFN-\u03b3 activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation","volume":"11","author":"Xiong","year":"2022","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.ejps.2025.107359_bib0021","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41578-023-00617-2","article-title":"Responsive biomaterials: optimizing control of cancer immunotherapy","volume":"9","author":"Xue","year":"2024","journal-title":"Nat. Rev. Mater."},{"issue":"1","key":"10.1016\/j.ejps.2025.107359_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.ejps.2025.107359_bib52","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/2326-6066.CIR-14-0226","article-title":"Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 TreatmentPD-L1 Blockade Overcomes Resistance to Anti-CD40 Therapy","volume":"3","author":"Zippelius","year":"2015","journal-title":"Cancer immunology research"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:25:53Z","timestamp":1773318353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":64,"alternative-id":["S0928098725003562"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107359","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implantable drug delivery system improves tolerability of anti-CD40\/anti-PD1 and chemotherapy in a murine model of breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107359"}}